Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294225000012 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864284070805504 |
|---|---|
| author | Jason C.S. Ho K.M. Cheung |
| author_facet | Jason C.S. Ho K.M. Cheung |
| author_sort | Jason C.S. Ho |
| collection | DOAJ |
| description | Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed data from three oncology centers in Hong Kong, covering the period from January 2019 to December 2022. Among the 123 patients who underwent definitive chemoradiation, 33 had common driver mutations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and RET fusions. The addition of durvalumab did not improve real-world recurrence-free survival (rwRFS) in patients with these mutations (hazard ratio [HR] 0.852, 95 % confidence interval [CI] 0.394 – 1.843, p= 0.683). In contrast, rwRFS significantly improved for patients without common mutations (HR 0.342, 95 % CI 0.203 – 0.577, p< 0.001). These findings suggest that consolidation durvalumab may not be beneficial for patients with common driver mutations, underscoring the need for personalized treatment strategies in this population. |
| format | Article |
| id | doaj-art-e6357736d1c9416e95a3cd998f2ae0c3 |
| institution | Kabale University |
| issn | 2468-2942 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj-art-e6357736d1c9416e95a3cd998f2ae0c32025-02-09T05:00:47ZengElsevierCancer Treatment and Research Communications2468-29422024-01-0142100863Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutationsJason C.S. Ho0K.M. Cheung1Corresponding author at: Department of Clinical Oncology, Queen Elizabeth Hospital, 30 Gascoigne Road, Hong Kong.; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, Hong KongDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, Hong KongUnresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed data from three oncology centers in Hong Kong, covering the period from January 2019 to December 2022. Among the 123 patients who underwent definitive chemoradiation, 33 had common driver mutations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and RET fusions. The addition of durvalumab did not improve real-world recurrence-free survival (rwRFS) in patients with these mutations (hazard ratio [HR] 0.852, 95 % confidence interval [CI] 0.394 – 1.843, p= 0.683). In contrast, rwRFS significantly improved for patients without common mutations (HR 0.342, 95 % CI 0.203 – 0.577, p< 0.001). These findings suggest that consolidation durvalumab may not be beneficial for patients with common driver mutations, underscoring the need for personalized treatment strategies in this population.http://www.sciencedirect.com/science/article/pii/S2468294225000012Non-small cell lung cancerChemoradiotherapyImmunotherapyDurvalumabReal-world data |
| spellingShingle | Jason C.S. Ho K.M. Cheung Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations Cancer Treatment and Research Communications Non-small cell lung cancer Chemoradiotherapy Immunotherapy Durvalumab Real-world data |
| title | Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations |
| title_full | Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations |
| title_fullStr | Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations |
| title_full_unstemmed | Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations |
| title_short | Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations |
| title_sort | brief report impact of consolidation durvalumab on unresectable non small cell lung cancer with driver mutations |
| topic | Non-small cell lung cancer Chemoradiotherapy Immunotherapy Durvalumab Real-world data |
| url | http://www.sciencedirect.com/science/article/pii/S2468294225000012 |
| work_keys_str_mv | AT jasoncsho briefreportimpactofconsolidationdurvalumabonunresectablenonsmallcelllungcancerwithdrivermutations AT kmcheung briefreportimpactofconsolidationdurvalumabonunresectablenonsmallcelllungcancerwithdrivermutations |